Loading
Loading
Product image is a representation โ actual packaging and label may vary.
Nasal Sprays ยท 7ml
๐ Pre-order โ ships from 31 August 2026
This product is pre-order only right now. Your order will be dispatched once stock arrives on 31 August 2026.
$125
AUD ยท 1 pack
Flat rate ยท ships with your order
VIP (Vasoactive Intestinal Peptide) is a 28-amino-acid neuropeptide studied in preclinical and clinical research for its broad neuroimmune and vasoregulatory properties. Research has examined its potential to relax smooth muscle, promote bronchodilation, regulate intestinal motility, modulate T-cell responses, suppress inflammatory cytokines, and support pulmonary arterial vasodilation. Studies have explored applications in pulmonary hypertension, autoimmune, and respiratory disease models.
Chemical Properties
Research Use Only โ Disclaimer
These consumable supplies are intended solely for use in research and laboratory settings. All items are sterile and individually packaged for professional handling. BAC water is for peptide reconstitution purposes only and is not intended for injection without appropriate professional supervision. Not for human or animal consumption in any form.
VIP
Vasoactive Intestinal Peptide
Vasoactive Intestinal Peptide (VIP) is a 28-amino-acid neuropeptide with broad physiological roles across the nervous, immune, and gastrointestinal systems. Widely distributed in central and peripheral neurons, intestinal mucosal cells, and immune tissue, VIP was first isolated from porcine intestine in 1970 and named for its pronounced vasodilatory effects. It is now recognised as one of the most pleiotropic neuroimmune regulators.
VIP acts via VPAC1 (ubiquitous) and VPAC2 (primarily CNS, immune) G-protein-coupled receptors that signal through cAMP/PKA and PKC cascades. In smooth muscle it causes potent relaxation (vasodilation, bronchodilation, intestinal relaxation). In immune cells, VPAC1/2 activation shifts the Th1/Th2 balance toward Th2/Treg anti-inflammatory responses, reducing TNF-ฮฑ, IL-6, and IL-12 while increasing IL-10 and TGF-ฮฒ. In the SCN it acts as a circadian coupling signal between pacemaker neurons.
Pulmonary arterial hypertension (inhaled VIP demonstrated acute pulmonary vasodilation in Phase 2 trials), inflammatory bowel disease (VIP is depleted in IBD mucosa; restoration reduces colitis severity in animal models), autoimmune conditions (rheumatoid arthritis, multiple sclerosis โ robust preclinical data), POTS and dysautonomia research, circadian rhythm modulation, neuroprotection, and Alzheimer's disease (VIP-ergic neurons are early casualties).
Key References
For research reference only. All information pertains to preclinical or published human trial data. Not intended as medical advice. This product is for research use only.
